Kyowa Hakko Kirin Plans Overseas Expansion As Global Specialty Pharma
This article was originally published in PharmAsia News
Kyowa Hakko Kirin President Nobuo Hanai said the company’s mid-term management plan starting next year includes policies to expand overseas with their antibody KW-0761.
You may also be interested in...
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.